ADMA BIOLOGICS, INC.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
(a) Sales of Unregistered Securities and Use of Proceeds
None.
(c) Repurchases of Securities
The table below reflects shares of common stock we repurchased during the third quarter of 2025.
Index
| For the Month Ended · Total Number of Shares Purchased (1) · Average Price Paid Per Share · Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(2) | ||||
|---|---|---|---|---|
| July 31, 2025 | - | $ | - | $485,002,210 |
| August 31, 2025 | 4,587 | $16.33 | $484,928,777 | |
| September 30, 2025 | 507,824 | $15.67 | $476,961,541 | |
| Total | 512,411 | $15.68 | ||
(1) Shares were repurchased pursuant to our share repurchase program publicly announced on May 5, 2025.
(2) There is no expiration date for this share repurchase program. The authorization to repurchase shares will end when we have repurchased the maximum number of shares authorized, or if we have determined to terminate such program.
Item 3.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.